| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Chemosensitivity and outcome of BRCA1- and BRCA2-associated ovarian cancer patients after first-line chemotherapy compared with sporadic ovarian cancer patients.
|
Ann Oncol
|
2011
|
1.54
|
|
2
|
Is TP53 dysfunction required for BRCA1-associated carcinogenesis?
|
Mol Cell Endocrinol
|
1999
|
1.12
|
|
3
|
Reduced expression of BAX is associated with poor prognosis in patients with epithelial ovarian cancer: a multifactorial analysis of TP53, p21, BAX and BCL-2.
|
Br J Cancer
|
2001
|
1.08
|
|
4
|
Tamoxifen resistance in breast cancer: elucidating mechanisms.
|
Drugs
|
2001
|
1.08
|
|
5
|
The prognostic value of epidermal growth factor receptors, determined by both immunohistochemistry and ligand binding assays, in primary epithelial ovarian cancer: a pilot study.
|
Eur J Cancer
|
1993
|
0.98
|
|
6
|
The impact of CYP2D6-predicted phenotype on tamoxifen treatment outcome in patients with metastatic breast cancer.
|
Br J Cancer
|
2010
|
0.94
|
|
7
|
Prognostic significance of germline BRCA2 mutations in hereditary breast cancer patients.
|
J Clin Oncol
|
2000
|
0.92
|
|
8
|
Killed Listeria monocytogenes vaccine is protective in C3H/HeJ mice without addition of adjuvants.
|
Nature
|
1980
|
0.92
|
|
9
|
Epidermal growth factor receptor in ovarian tumours: correlation of immunohistochemistry with ligand binding assay.
|
Br J Cancer
|
1992
|
0.92
|
|
10
|
CYP2D6 genotype in relation to tamoxifen efficacy in a Dutch cohort of the tamoxifen exemestane adjuvant multinational (TEAM) trial.
|
Breast Cancer Res Treat
|
2013
|
0.88
|
|
11
|
Prognostic factors and response to therapy in breast cancer.
|
Cancer Surv
|
1993
|
0.88
|
|
12
|
Androgen-dependent growth regulation of and release of specific protein(s) by the androgen receptor containing human prostate tumor cell line LNCaP.
|
Prostate
|
1986
|
0.88
|
|
13
|
Genetic alterations in ovarian borderline tumours and ovarian carcinomas.
|
Eur J Obstet Gynecol Reprod Biol
|
1999
|
0.86
|
|
14
|
Expression of urokinase-type plasminogen activator (uPA) and its inhibitor PAI-1 in benign, borderline, malignant primary and metastatic ovarian tumors.
|
Int J Cancer
|
1996
|
0.85
|
|
15
|
High prevalence of codon 213Arg-->Stop mutations of the TP53 gene in human ovarian cancer in the southwestern part of The Netherlands.
|
Int J Cancer
|
1998
|
0.85
|
|
16
|
Sporadic CDKN2 (MTS1/p16ink4) gene alterations in human ovarian tumours.
|
Br J Cancer
|
1996
|
0.84
|
|
17
|
Prognostic significance of TP53 accumulation in human primary breast cancer: comparison between a rapid quantitative immunoassay and SSCP analysis.
|
Int J Cancer
|
1996
|
0.83
|
|
18
|
Cell biological factors associated with the response of breast cancer to systemic treatment.
|
Cancer Treat Rev
|
1993
|
0.82
|
|
19
|
Determination of steroid hormone-dependency of tumours utilizing tissue sections. Survey of histochemical techniques and their application in surgical pathology.
|
J Pathol
|
1986
|
0.81
|
|
20
|
Ki-67 staining in benign, borderline, malignant primary and metastatic ovarian tumors: correlation with steroid receptors, epidermal-growth-factor receptor and cathepsin D.
|
Int J Cancer
|
1994
|
0.81
|
|
21
|
Altered expression of p53 and its regulated proteins in phyllodes tumours of the breast.
|
J Pathol
|
1999
|
0.81
|
|
22
|
Molecular genetic evidence for unifocal origin of advanced epithelial ovarian cancer and for minor clonal divergence.
|
Br J Cancer
|
1995
|
0.80
|
|
23
|
Additional value of the 70-gene signature and levels of ER and PR for the prediction of outcome in tamoxifen-treated ER-positive breast cancer.
|
Breast
|
2012
|
0.80
|
|
24
|
Pleiotropic actions of suramin on the proliferation of human breast-cancer cells in vitro.
|
Int J Cancer
|
1992
|
0.79
|
|
25
|
Changes of oestrogen receptor levels in Leydig cells from mice and rats during culture.
|
J Steroid Biochem
|
1985
|
0.77
|
|
26
|
Prognostic value of TP53 gene mutation in adjuvant treated breast cancer patients.
|
Breast Cancer Res Treat
|
2001
|
0.76
|
|
27
|
Rapid and sensitive detection of oestrogen receptors in cells and tissue sections by autoradiography with 125I-oestradiol.
|
Histochem J
|
1985
|
0.75
|
|
28
|
Fluorescent ligands, used in histocytochemistry, do not discriminate between estrogen receptor-positive and receptor-negative human tumor cell lines.
|
Breast Cancer Res Treat
|
1984
|
0.75
|
|
29
|
Fluorescent androgen derivatives do not discriminate between androgen receptor-positive and -negative human tumor cell lines.
|
Prostate
|
1984
|
0.75
|